Fate Therapeutics (NASDAQ: FATE) up 16.2%; reported Q2 EPS of ($0.23), $0.01 better than the analyst estimate of ($0.24). Revenue ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE